BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:56@myasthenia.org
DTSTART;TZID=America/New_York:20221011T210000
DTEND;TZID=America/New_York:20221011T220000
DTSTAMP:20241028T210259Z
URL:https://myasthenia.org/events/2022-research-series-update-of-musk-myas
 thenia-gravis-phase-1-clinical-trial-muscaartes-2022-10-11/
SUMMARY:2022 Research Series: Update of MuSK Myasthenia Gravis Phase 1 Clin
 ical Trial\n        (MusCAARTes)
DESCRIPTION:Update of MuSK Myasthenia Gravis Phase 1 Clinical Trial (MusCAA
 RTes) Oct 11th | 2pm (Eastern) 11am (Pacific)  - Review of data that suppo
 rted IND submission and clearance by the FDA - Discuss the purpose of clin
 ical trials - Present the design of the MusCAARTes Phase 1 clinical trial 
 for patients with MuSK Myasthenia Gravis   The presenter will be David Cha
 ng\, M.D.\, M.P.H.\, Chief Medical Officer at Cabaletta Bio.  Watch here: 
  
ATTACH;FMTTYPE=image/jpeg:https://myasthenia.org/wp-content/uploads/Portal
 s/0/EasyDNNNews/275/david-chang-webinar-2022-3.jpg
CATEGORIES:Events,Webinars
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
DTSTART:20220313T030000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR